David M. Weber - 31 Mar 2022 Form 4 Insider Report for ABIOMED INC

Reporting relationship
CHIEF OPERATING OFFICER
Issuer ticker
N/A
Reported as of
31 Mar 2022
Net transaction value
-$2,550,000
Source evidence Original filing metadata and source links for verification. 4 source fields
SEC form
4
Accepted by SEC
04 Apr 2022, 17:07:49 UTC
Prior SEC filing
18 Feb 2022
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Marc A. Began (by power of attorney)

Key filing fact

David M. Weber filed Form 4 for ABIOMED INC on 04 Apr 2022.

Key facts

  • This page summarizes David M. Weber's Form 4 filing for ABIOMED INC.
  • 1 reported transaction and 7 derivative rows are listed below.
  • Accepted by SEC: 04 Apr 2022, 17:07.

Change

  • Previous filing in this sequence was filed on 18 Feb 2022.
  • Current net transaction value: -$2,550,000.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

NASD transaction

Common Stock, $.01 par value

Sale

Transaction value
$2,550,000
Shares
-7,500
Change %
-6.1%
Price
$340.00*
Shares after
116,314
Date
31 Mar 2022
Ownership
Direct
Footnotes
F1, F2
NASD holding

Common Stock, $.01 par value

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
15,497
Date
31 Mar 2022
Ownership
By Trust

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

NASD holding Derivative

Stock Option (right to buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
10,000
Date
31 Mar 2022
Ownership
Direct
Underlying class
Common Stock
Underlying amount
0
Exercise price
$66.25
Footnotes
F3, F4
NASD holding Derivative

Stock Option (right to buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
7,000
Date
31 Mar 2022
Ownership
Direct
Underlying class
Common Stock
Underlying amount
0
Exercise price
$99.62
Footnotes
F4, F5
NASD holding Derivative

Stock Option (right to buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
8,000
Date
31 Mar 2022
Ownership
Direct
Underlying class
Common Stock
Underlying amount
0
Exercise price
$134.51
Footnotes
F4, F5
NASD holding Derivative

Stock Option (right to buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
6,500
Date
31 Mar 2022
Ownership
Direct
Underlying class
Common Stock
Underlying amount
0
Exercise price
$381.97
Footnotes
F4, F5
NASD holding Derivative

Stock Option (right to buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
6,000
Date
31 Mar 2022
Ownership
Direct
Underlying class
Common Stock
Underlying amount
0
Exercise price
$266.39
Footnotes
F4, F5
NASD holding Derivative

Stock Option (right to buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
5,000
Date
31 Mar 2022
Ownership
Direct
Underlying class
Common Stock
Underlying amount
0
Exercise price
$223.90
Footnotes
F4, F5
NASD holding Derivative

Stock Option (right to buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
4,969
Date
31 Mar 2022
Ownership
Direct
Underlying class
Common Stock
Underlying amount
0
Exercise price
$283.88
Footnotes
F4, F5
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 5 footnotes

Footnote F1

Sale of common stock pursuant to reporting owner's 10b5-1 plan.

Footnote F2

This price represents the sale price of the transactions on the reported date at $340.00. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer.

Footnote F3

Grant to reporting person of option to buy the number of shares of Common Stock set forth in Table II, Column 7, under the ABIOMED, Inc. 2008 Stock Incentive Plan.

Footnote F4

These options become exercisable in annual 33-1/3% increments, commencing on the date shown in Table II, Column 6.

Footnote F5

Grant to reporting person of option to buy the number of shares of Common Stock set forth in Table II, Column 7, under the ABIOMED, Inc. 2015 Omnibus Incentive Plan.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .